NCT00028015已完成2 期
A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 14
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent or metastatic colorectal cancer.
详细描述
OBJECTIVES:
- Determine the efficacy of SarCNU in patients with recurrent or metastatic colorectal cancer.
- Determine the qualitative and quantitative toxicity of this drug in these patients.
- Determine the time to progression and survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral SarCNU on days 1, 5, and 9. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) receive 2 additional courses beyond documentation of CR. Patients who achieve partial response (PR) receive 4 additional courses beyond documentation of PR.
Patients are followed at 4 weeks and then every 3 months thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (14)
Loading locations...
相似试验
已完成
2 期
SarCNU in Treating Patients With Recurrent Malignant GliomaBrain and Central Nervous System TumorsNCT00036660NCIC Clinical Trials Group10
Unknown
2 期
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerLung CancerNCT00003562Hope Cancer Institute, Inc.38
已完成
1 期
Chemotherapy in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00003703Jewish General Hospital
终止
2 期
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung CancerLung CancerNCT00003847Vertex Pharmaceuticals Incorporated36
Unknown
2 期
Chemotherapy in Treating Patients With Liver CancerLiver CancerNCT00003044Matrix Pharmaceutical55